基于“肠肝轴”探析代谢相关性脂肪性肝病中西医发病演变规律

doi:10.3969/j.issn.1672-5069.2026.02.002

实用肝脏病杂志 ›› 2026, Vol. 29 ›› Issue (2): 166-169.doi: 10.3969/j.issn.1672-5069.2026.02.002

基于“肠肝轴”探析代谢相关性脂肪性肝病中西医发病演变规律

赵钊, 陈星宇, 马振东, 隋晓丹

130000 长春市长春中医药大学(赵钊,马振东);附属医院肝脾胃病科(陈星宇,隋晓丹)

收稿日期:2025-07-30 出版日期:2026-03-10 发布日期:2026-03-13
通讯作者: 隋晓丹,E-mail:79883291@qq.com
作者简介:赵钊,女,26岁,医学硕士。E-mail:3076360239@qq.com
基金资助:
^*吉林省定西市科研计划项目(编号:DX2024BY010)

Chinese and western medical pathogenesis of metabolic-related fatty liver disease based on the“gut-liver axis”

Zhao Zhao, Chen Xingyu, Ma Zhendong, et al

Department of Liver, Spleen and Stomach Diseases, Affiliated Hospital, Changchun University of Traditional Chinese Medicine, Changchun 130000, Jilin Province, China

Received:2025-07-30 Online:2026-03-10 Published:2026-03-13

摘要/Abstract

关键词: 代谢相关性脂肪性肝病, 肠道菌群, 发病机制, 肠肝轴

Key words: Metabolic-related fatty liver disease, Intestinal flora, Pathogenesis, Gut-liver axis

赵钊, 陈星宇, 马振东, 隋晓丹. 基于“肠肝轴”探析代谢相关性脂肪性肝病中西医发病演变规律[J]. 实用肝脏病杂志, 2026, 29(2): 166-169.

Zhao Zhao, Chen Xingyu, Ma Zhendong, et al. Chinese and western medical pathogenesis of metabolic-related fatty liver disease based on the“gut-liver axis”[J]. Journal of Practical Hepatology, 2026, 29(2): 166-169.

参考文献

[1] Zeng J,Fan J G. From NAFLD to MAFLD:Not just a change in the name. Hepatobiliary Pancreat Dis Int,2022,21(6):511-513.
[2] Mantovani A,Scorletti E,Mosca A,et al. Complications,morbidity and mortality of nonalcoholic fatty liver disease. Metabolism,2020,111S:154170.
[3] Chan K E,Koh T J L,Tang A S P,et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease:A meta-analysis and systematic review of 10739607 individuals. J Clin Endocrinol Metab,107,9 (2022):2691-2700.
[4] Riazi K,Azhari H,Charette J H,et al. The prevalence and incidence of NAFLD worldwide:A systematic review and meta-analysis. Lancet Gastroenterol Hepatol,2022,7(9):851-861.
[5] Fouad Y,Alboraie M,Shiha G. Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease. Hepatol Int,2024,18(Suppl 2):827-833.
[6] 姚树坤,刘婧,周天惠.代谢相关脂肪性肝病的发病机制与中医病机.临床肝胆病杂志,2024,40(10):1954-1958.
[7] 董博一,杜琳.基于“浊毒”理论及肠道微生态紊乱探究针刺治疗非酒精性脂肪性肝炎.中西医结合肝病杂志,2025,35(4):472-476.
[8] 熊壮,孟香彤,沈东,等.刘铁军“脏毒腑秽学说”的构建与应用.长春中医药大学学报,2021,37(4):763-766.
[9] Tripathi A,Debelius J,Brenner,et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol,2018,15(7):397-411.
[10] 段旭冰,陈文慧,王仕奇,等.非酒精性脂肪性肝病伏邪“痰浊脂膏”与脂稳态关系探究.中华中医药杂志,2021,36(12):7099-7102.
[11] 隋晓丹,邓厚波,刘铁军.中医对非酒精性脂肪肝病机辩证研究进展.中国实用医药,2013,8(26):247-248.
[12] 万俊阳,王岩,张明香.基于“浊毒”理论探讨脂质代谢异常与代谢相关脂肪性肝病.中医临床研究,2022,14(10):97-100.
[13] 王梦依,汪卓,刘洋.肠道菌群调控脂质代谢作用与机制的研究进展.微生物学通报,2025,52(3):917-930.
[14] Ouyang S,Zhuo S,Yang M,et al. Glycerol kinase drives hepatic de novo lipogenesis and triglyceride synthesis in nonalcoholic fatty liver by activating SREBP-1c transcription,upregulating DGAT1/2 expression,and promoting glycerol metabolism. Adv Sci (Weinh),2024,11(46):e2401311.
[15] Brütting C,Lara Bisch M,Brandsch C,et al. Impact of dietary propionate on fructose-induced changes in lipid metabolism,gut microbiota and short-chain fatty acids in mice. Int J Food Sci Nutr,2021,72(2):160-173.
[16] Xu H,Fang F,Wu K,et al. Gut microbiota-bile acid crosstalk regulates murine lipid metabolism via the intestinal FXR-FGF19 axis in diet-induced humanized dyslipidemia. Microbiome,2023,11(1):262.
[17] Clifford B L,Sedgeman L R,Williams K J,et al. FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. Cell Metab,2021,33(8):1671-1684.
[18] Syed-Abdul M M. Lipid metabolism in metabolic-associated steatotic liver disease (MASLD). Metabolites,2023,14(1):12.
[19] Pinanga Y D,Pyo K H,Shin E A,et al. Association between hepatocyte TM4SF5 expression and gut microbiome dysbiosis during non-alcoholic fatty liver disease development. Life Sci,2024,358:123164.
[20] Mou Y,Du Y,Zhou L,et al. Gut microbiota interact with the brain through systemic chronic inflammation: implications on neuroinflammation,neurodegeneration,and aging. Front Immunol,2022,13:796288.
[21] 李欣,吴伟华.肠道稳态与慢性低度系统性炎症.医学综述,2018,24(7):1354-1359.
[22] 孙智媛,陈凤鸣,钟颂石,等.肠-肝轴:肠道微生态与动物肝脏疾病.中国兽医学报,2022,42(1):175-182.
[23] Sehgal R,de Mello V D,Männistö V,et al. Indolepropionic acid,a gut bacteria-produced tryptophan metabolite and the risk of type 2 diabetes and non-alcoholic fatty liver disease. Nutrients,2022,14(21):4695.
[24] Chen C Y,Ho H C. Roles of gut microbes in metabolic-associated fatty liver disease. Tzu Chi Med J,2023,35(4):279-289.
[25] Olona A,Hateley C,Muralidharan S,et al. Sphingolipid metabolism during Toll-like receptor 4 (TLR4)-mediated macrophage activation. Br J Pharmacol,2021,178(23):4575-4587.
[26] Mou W L,Chen S R,Wu Z T,et al. LPS-TLR4/MD-2-TNF-α signaling mediates alcohol-induced liver fibrosis in rats. J Toxicol Pathol,2022,35(2):193-203.
[27] He S,Cui S,Song W,et al. Interleukin-17 weakens the NAFLD/NASH process by facilitating intestinal barrier restoration depending on the gut microbiota. mBio,2022,13(2):e0368821.
[28] Zhang W,Liu K,Ren G M,et al. BRISC is required for optimal activation of NF-κB in Kupffer cells induced by LPS and contributes to acute liver injury. Cell Death Dis,2023,14(11):743.
[29] 李姗,周志文,刘湘花,等.黄杞苷干预NF-κB信号通路抑制巨噬细胞炎症反应及氧化应激.中国感染控制杂志,2023,22(4):383-390.
[30] 徐佳浩,梁计陵,李佳航,等.运动改善小鼠非酒精性脂肪肝纤维化的生物信息学分析.中国康复医学杂志,2025,40(7):986-994.
[31] Zhang M,Serna-Salas S,Damba T,et al. Hepatic stellate cell senescence in liver fibrosis:Characteristics,mechanisms and perspectives. Mech Ageing Dev,2021,199:111572.
[32] 郑博文,王佳慧,罗淑娟,等.肠道菌群丰度和多样性对肝纤维化的加速或延缓作用及特殊菌群的防治研究进展.中国药理学与毒理学杂志,2022,36(3):217-224.
[33] Su X,Gao Y,Yang R. Gut microbiota derived bile acid metabolites maintain the homeostasis of gut and systemic immunity. Front Immunol,2023,14:1127743.
[34] Yang D,Wei X,Zhang B,et al. Probiotics protect against hepatic steatosis in tris (2-chloroethyl) phosphate-induced metabolic disorder of mice via FXR signaling. Food Chem Toxicol,2022,169:113440.
[35] Sørensen M D,Thiele M,Krag A,et al. Stage-dependent expression of fibrogenic markers in alcohol-related liver disease. Pathol Res Pract,2022,231:153798.
[36] Li D,Feng Y,Tian M,et al. Gut microbiota-derived inosine from dietary barley leaf supplementation attenuates colitis through PPARγ signaling activation. Microbiome,2021,9(1):83.
[37] Qiu Y Y,Zhang J,Zeng F Y,et al. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). Pharmacol Res,2023,192:106786.
[38] Pastore M,Caligiuri A,Raggi C,et al. Macrophage MerTK promotes profibrogenic cross-talk with hepatic stellate cells via soluble mediators. JHEP Rep,2022,4(4):100444.
[39] Riva A,Gray E H,Azarian S,et al. Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis. JHEP Rep,2020,2(6):100151.
[40] Akkız H,Gieseler R K,Canbay A. Liver fibrosis:From basic science towards clinical progress,focusing on the central role of hepatic stellate cells. Int J Mol Sci,2024,25(14):7873.

基于“肠肝轴”探析代谢相关性脂肪性肝病中西医发病演变规律

Chinese and western medical pathogenesis of metabolic-related fatty liver disease based on the“gut-liver axis”

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	代子行, 袁慧, 陈庆灵, 朱传龙, 李毓雯. 代谢相关性脂肪性肝病患者吸入性有机化合物与炎症指标的关系:基于2017～2020年美国国家健康与营养调查数据库资料分析^*[J]. 实用肝脏病杂志, 2025, 28(3): 350-353.
[2]	苏雅, 王炳元. 酒精性肝病不是代谢相关性脂肪性肝病[J]. 实用肝脏病杂志, 2025, 28(1): 5-8.
[3]	柳雅立, 张晶. 儿童和青少年代谢相关脂肪性肝病研究进展^*[J]. 实用肝脏病杂志, 2024, 27(4): 488-491.
[4]	杨蕊旭, 齐明华. 慢性HBV感染合并代谢相关性脂肪性肝病患者抗病毒治疗对策^*[J]. 实用肝脏病杂志, 2023, 26(6): 773-776.
[5]	施漪雯, 范建高. 代谢相关性脂肪性肝病流行现状[J]. 实用肝脏病杂志, 2023, 26(6): 777-780.
[6]	侯义林, 曹风华, 纪小燕, 蔡燕. 非酒精性脂肪性肝病患者肠道菌群及血清IL-17和INF-γ水平变化^*[J]. 实用肝脏病杂志, 2023, 26(6): 819-822.
[7]	张淮, 郑明华. MAFLD高危人群的筛查和分层管理^*[J]. 实用肝脏病杂志, 2023, 26(4): 463-465.
[8]	陈慧婷, 周永健. 慢性胆汁淤积性肝病患者肠-肝轴功能变化研究进展^*[J]. 实用肝脏病杂志, 2023, 26(3): 305-307.
[9]	张绍全, 林炳亮. 肠道菌群与肝硬化研究进展^*[J]. 实用肝脏病杂志, 2023, 26(3): 313-316.
[10]	王凌云, 周永健. 肠道菌群与自身免疫性肝炎研究进展^*[J]. 实用肝脏病杂志, 2023, 26(3): 317-319.
[11]	苏佩华, 宋枚芳, 赵彩彦. 慢性乙型肝炎合并非酒精性脂肪性肝病与肝细胞癌[J]. 实用肝脏病杂志, 2023, 26(3): 445-448.
[12]	黄淡霞, 招志辉, 萧月兴, 何艳青. 小檗碱通过调节肠道菌群改善高脂饮食诱导的非酒精性脂肪性肝病大鼠肝组织炎症实验研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 23-26.
[13]	罗楠, 李荣宽. 肝硬化并发自发性细菌性腹膜炎诊治现状[J]. 实用肝脏病杂志, 2022, 25(5): 616-619.
[14]	米朦, 卢秉久, 王学良, 王晓彤, 郑佳连. 代谢相关性脂肪性肝病患者血脂分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 653-656.
[15]	王芳, 高晓霞, 汪庆强. 黄连解毒汤联合益生菌制剂对非酒精性脂肪性肝炎患者中医症候积分和肠道菌群平衡的影响^*[J]. 实用肝脏病杂志, 2022, 25(2): 235-238.